Skip to main content

Table 3 Baseline and post-treatment EORTC QLQ-C15-PAL scores

From: Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide

EORTC QLQ-C15-PAL scalea Octreotide (N = 52)
mean scores (95% CI)
Placebo (N = 54)
mean scores (95% CI)
Baseline Post-treatment p-value Baseline Post-treatment p-value
Overall quality of lifeb 22.08 (14.32, 29.85)
n = 40
30.81 (22.57, 39.05)
n = 33
0.205 31.48 (22.26, 40.70)
n = 36
32.22 (21.27, 43.18)
n = 30
0.778
Physical functioningb 27.69 (19.69, 35.69)
n = 39
32.44 (22.51, 42.36)
n = 30
0.204 31.17 (22.80, 39.53)
n = 40
30.00 (19.70, 40.27)
n = 30
0.831
Emotional functioningb 57.65 (47.35, 67.94)
n = 36
71.80 (60.78, 82.82)
n = 26
0.059 55.25 (45.26, 65.24)
n = 35
63.22 (50.20, 76.25)
n = 29
0.074
Fatiguec 74.09 (67.21, 80.97)
n = 39
71.88 (63.37, 80.40)
n = 32
0.107 74.10 (67.84, 80.35)
n = 39
71.88 (60.27, 83.48)
n = 32
0.965
Nausea & vomitingc 73.18 (62.34, 84.01)
n = 41
40.70 (27.56, 53.83)
n = 34
0.001 60.53 (50.55, 70.51)
n = 38
35.95 (23.63, 48.26)
n = 32
0.016
Painc 60.16 (49.33, 71.00)
n = 41
43.94 (32.23, 55.65)
n = 33
0.007 55.42 (45.01, 65.83)
n = 40
42.93 (30.48, 55.38)
n = 33
0.026
Dyspnoeac 40.65 (29.74, 51.56)
n = 41
32.32 (21.88, 42.76)
n = 33
0.077 36.75 (27.89, 45.62)
n = 39
27.08 (14.34, 39.83)
n = 32
0.008
Insomniac 45.83 (34.59, 57.08)
n = 40
33.33 (22.28, 44.39)
n = 33
0.013 46.67 (34.89, 58.44)
n = 40
47.92 (32.67, 63.16)
n = 32
0.868
Appetite lossc 74.17 (62.98, 85.36)
n = 40
56.25 (43.50, 69.00)
n = 32
0.034 82.05 (74.27, 89.83)
n = 39
57.58 (43.63, 71.52)
n = 33
0.002
Constipationc 67.50 (56.05, 78.95)
n = 40
50.00 (36.19, 63.81)
n = 34
0.027 67.50 (56.31, 78.69)
n = 40
52.53 (38.35, 66.71)
n = 33
0.027
  1. Bolded numbers indicate statistically significant differences
  2. HrQoL Health-related quality of life
  3. amean unadjusted within-group paired differences between baseline and post-treatment scores were analysed using the Wilcoxon Signed Rank test. b higher scores represent better outcomes; c higher scores represent greater symptom burden